Nektar Therapeutics (NASDAQ:NKTR) CFO Gil M. Labrucherie sold 3,767 shares of the firm’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $31.37, for a total value of $118,170.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Gil M. Labrucherie also recently made the following trade(s):
- On Tuesday, February 19th, Gil M. Labrucherie sold 3,592 shares of Nektar Therapeutics stock. The stock was sold at an average price of $42.39, for a total value of $152,264.88.
Shares of NASDAQ:NKTR traded up $0.68 on Friday, hitting $32.02. 1,480,671 shares of the company’s stock were exchanged, compared to its average volume of 1,752,666. Nektar Therapeutics has a 12 month low of $29.22 and a 12 month high of $92.17. The company has a market cap of $5.91 billion, a price-to-earnings ratio of 8.47 and a beta of 2.96. The company has a current ratio of 14.94, a quick ratio of 14.83 and a debt-to-equity ratio of 0.21.
Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.03. The firm had revenue of $28.22 million for the quarter, compared to analyst estimates of $25.45 million. Nektar Therapeutics had a return on equity of 37.63% and a net margin of 55.65%. During the same quarter last year, the firm posted ($0.60) earnings per share. As a group, equities research analysts predict that Nektar Therapeutics will post -3.14 EPS for the current fiscal year.
Several analysts have recently weighed in on NKTR shares. Mizuho reiterated a “buy” rating and set a $81.00 target price on shares of Nektar Therapeutics in a research report on Wednesday, January 23rd. ValuEngine downgraded Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 31st. HC Wainwright reiterated a “hold” rating and set a $47.00 target price on shares of Nektar Therapeutics in a research report on Tuesday, February 19th. BMO Capital Markets started coverage on Nektar Therapeutics in a research report on Friday, February 22nd. They set an “outperform” rating and a $75.00 target price for the company. Finally, TheStreet upgraded Nektar Therapeutics from a “d+” rating to a “c” rating in a research report on Thursday, February 28th. One analyst has rated the stock with a sell rating, four have given a hold rating and nine have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $69.73.
Institutional investors have recently made changes to their positions in the company. Meeder Asset Management Inc. increased its stake in shares of Nektar Therapeutics by 150.2% during the first quarter. Meeder Asset Management Inc. now owns 798 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 479 shares during the period. Quantamental Technologies LLC purchased a new position in shares of Nektar Therapeutics during the first quarter valued at $27,000. CSat Investment Advisory L.P. increased its stake in shares of Nektar Therapeutics by 279.2% during the fourth quarter. CSat Investment Advisory L.P. now owns 1,073 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 790 shares during the period. Laurel Wealth Advisors LLC purchased a new position in shares of Nektar Therapeutics during the fourth quarter valued at $39,000. Finally, Sandy Spring Bank purchased a new position in shares of Nektar Therapeutics during the fourth quarter valued at $59,000. Hedge funds and other institutional investors own 94.90% of the company’s stock.
WARNING: This story was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2019/05/17/nektar-therapeutics-nktr-cfo-gil-m-labrucherie-sells-3767-shares.html.
Nektar Therapeutics Company Profile
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.
Featured Article: What are catch-up contributions?
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.